Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONCY $1.00 0.1800 +21.95%
ZIOP $3.32 0.2600 +8.50%
SRNE $4.22 0.2400 +6.03%
AEZS $1.12 0.0600 +5.66%
ONTX $4.86 0.2100 +4.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BIND $8.05 -0.8900 -9.96%
GALE $2.05 -0.1600 -7.24%
ARRY $3.59 -0.2800 -7.24%
APRI $1.48 -0.1000 -6.33%
ONTY $1.80 -0.1200 -6.25%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer

(Yahoo! Finance) Mar 25, 2011 - Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer.
read article 

Mouse Cancer Genome Unveils Genetic Errors in Human Cancers

(WUSL) Mar 23, 2011 - For the current study, the investigators inserted into the mouse genome a human fusion gene, called PML-RARA, which is known to initiate APL in patients. Then, they waited a year for full-blown leukemia to develop.
read press release 

Novel Combination Chemotherapy for Localized Ewing Sarcoma

(NCI Cancer Bulletin) Mar 22, 2011 – Name of Trial: Phase III Randomized Study of Adding Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide to Standard Chemotherapy in Patients with Non-Metastatic Extracranial Ewing Sarcoma (COG-AEWS1031). See the protocol summary.
read article 

Study Identifies Tumor Suppressor with Ties to Common Cancers

(Beth Israel Deaconess Medical Center) Mar 23, 2011 - PinX1 protein could be an important target for cancer therapies.
read press release 

UCLA's Cancer 'Roadmap' Could Help Combat Resistance to Targeted Drug Therapies

(UCLA) Mar 24, 2011 - New drugs that specifically target the mutated genes responsible for cancer growth have shown great success in extending the lives of patients, with far fewer side effects than conventional anti-cancer therapies.
read press release 

Fish Stripes Give Clues to Fight Melanoma

(UMass Medical School) Mar 24, 20 11- Looking at the dark stripes on the tiny zebrafish you might not expect that they hold a potentially important clue to discovering a treatment for the deadly skin disease melanoma.
read press release 

Experts Debate: What's Best Way to Screen for Colon Cancer?

(Boston Globe/Daily Dose Blog) Mar 24, 2011- Two experts from Harvard Medical School -- Dr. John Saltzman, director of endoscopy at Brigham and Women's Hospital, and Dr. John Abramson, lecturer in health care policy -- explain their conflicting views on whether colonosopy is the best way to screen for colon cancer.
read article (free registration required) 

Science: The 'War on Cancer' Turns 40

(LAT/Booster Shots Blog) Mar 25, 2011 - In December 1971, President Nixon signed the National Cancer Act, which provided additional funds for the National Cancer Institute and symbolically launched what came to be known as the "War on Cancer."
read article (free registration required) 

Cephalon Wins Fentora Patent Suit Against Watson

(CNBC/Associated Press) Mar 25, 2011 - A U.S. District Court upheld one of the patent's supporting Cephalon Inc.'s drug Fentora, preventing competitor Watson Pharmaceuticals Inc. from selling a generic version of the powerful painkiller.
read article 

Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study

(U.S. News & World Report) Mar 25, 2011 - Just six months of hormone therapy, along with radiation, cuts the risk of dying from locally advanced prostate cancer in half when compared to radiation alone, researchers report
read article 

New Prostate Cancer Treatment Doubles Survival Rates

(University of Newcastle Australia) Mar 25, 2011 - Published in the latest edition of The Lancet Oncology, research showed that combining radiotherapy with six months of hormone therapy significantly reduced the death rate of prostate cancer patients.
read press release 

Cancer Survival

(New York Times Blog) Mar 24, 2011 - What about those cancer survival rates that a lot of people, including Senator Johnson, cite when asserting US medical superiority?
read article (free registration required) 

Cephalon Wins Ruling in Bid to Block Watson’s Fentora Copy

(Bloomberg) Mar 24, 2011 - Cephalon Inc. won a U.S. court ruling that may keep Watson Pharmaceuticals Inc. from selling generic versions of the painkiller Fentora until a patent expires in 2019.
read article 

Pfizer Drug Slows Pancreatic Tumors in New Attack on Cancer

(Bloomberg Businessweek) Mar 24, 2011 - An experimental drug made by Pfizer Inc. slowed deadly pancreatic cancer in a study that revealed a new treatment approach that tricks the immune system to attack tissue protecting tumors, researchers said.
read article 

Genzyme Drug Sees New Supply Disruption

(Boston Globe) Mar 24, 2011 - Genzyme Corp., set to turn over its business to a new owner this spring, yesterday told patients who take its Fabrazyme drug that they may have to delay or miss one or more doses over the next few months because of a new supply disruption at its Allston Landing plant.
read article (free registration required) 

Protalix Plans Human Clinical Tests of Medication for Rare Fabry's Disease

(Bloomberg) Mar 24, 2011 - Protalix BioTherapeutics Ltd., an Israeli biotechnology company, plans to start clinical trials of a drug treating Fabry disease this year and a medication against rheumatoid arthritis in early 2012.
read article 

Amgen Says Prolia Increases Bone Density Over Time

(CNBC) Mar 23, 2011 - Amgen Inc's Prolia bone drug continues to improve bone mineral density in post-menopausal women treated with the drug for up to five years, according to new data released on Wednesday.
read article 

US Regulator Clears Heartburn Drugs After Fracture Risk Found to be Unlikely

( Mar 24, 2011 - The US Food and Drug Administration (FDA) said over-the-counter heartburn drugs such as Prevacid and Prilosec do not appear to be associated with an increased chance of fractures and scrapped plans to update the drug labels to warn consumers of such a risk, The Wall Street Journal reported Thursday.
read article 

Branded Drug Prices Soar as Generic Pressure Rises

(Reuters) Mar 23, 2011 - U.S. prices for brand-name drugs are rising faster than ever as patents expire on top-selling medicines and the pharmaceutical industry nervously eyes the future of healthcare reform.
read article 

Preview-Bristol-Myers Melanoma Drug May Soon Hit US Market

(Reuters) Mar 23, 2011 - Bristol-Myers Squibb may win U.S. approval as early as this week for the first drug shown to extend survival for patients with a deadly form of skin cancer.
read article 

Baylor University Medical Center Opens North Texas' Largest Outpatient Cancer Center

(Baylor Health System) Mar 18, 2011 - Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas' largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26.
read press release 

American Society of Clinical Oncologists to Honor James P. Wilmot Cancer Center Physician

(URMC) Mar 23, 2011 - John M. Bennett, M.D., an international expert in leukemia, has been named the 2011 recipient of the B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. The award is given by the American Society of Clinical Oncologists (ASCO) and will be presented at the group’s 47th Annual Meeting, which will be held June 3-7, in Chicago.
read press release 

IntelliDose and Allscripts Partnership Gains Momentum

(CNBC) Mar 23, 2011 - Six oncology centers across the country are adding IntelliDose® software for oncology-specific functions to their Allscripts™ Electronic Health Record (EHR) systems.
read article 

Cephalon Taps Champions for Preclinical Tumorgraft Evaluation of Two Cancer Candidates

(GEN News) Mar 24, 2011 - Cephalon is paying Champions Biotechnology $1.39 million over the next year as part of a collaboration to evaluate the potential clinical activity of Cephalon’s CEP-32496 and CEP-37400 cancer compounds using Champions’ preclinical Tumorgraft™ technology platform.
read article 

Amgen Dividend May Come Next Month as Investors Seek Value From Cash Hoard

(Bloomberg) Mar 24, 2011 - Amgen Inc. may introduce its first dividend next month, rewarding investors whose stock in the world’s largest biotechnology company has fallen 33 percent since 2006, even as its cash hoard grew to $17.4 billion.
read article